FDA : Shots - Health News FDA

Luke Whitbeck, 2, sits on his mother's lap while the nurse prepares his treatment at a pediatric infusion center in Hawthorne, N.Y., in October 2016. Heidi de Marco/Kaiser Health News hide caption

toggle caption
Heidi de Marco/Kaiser Health News

High Prices For Orphan Drugs Strain Families And Insurers

  • Download
  • <iframe src="https://www.npr.org/player/embed/509507035/510301401" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
NPR, Kaiser Health News/Evaluate Pharma analysis for Kaiser Health News on Sept. 21, 2016

Drugs For Rare Diseases Have Become Uncommonly Rich Monopolies

  • Download
  • <iframe src="https://www.npr.org/player/embed/509506836/510204623" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Rep. Tim Murphy, R-Pa., embraces Rep. Fred Upton, R-Mich., during a media briefing about the 21st Century Cures Act on Capitol Hill on Nov. 30. Susan Walsh/AP hide caption

toggle caption
Susan Walsh/AP

Rep. Diana DeGette, D-Colo., and Rep. Fred Upton (right), R-Mich., who have spearheaded the 21st Century Cures Act, speak after a 2015 House of Representatives vote in its favor. Congressional Quarterly/CQ-Roll Call, Inc./Getty Images hide caption

toggle caption
Congressional Quarterly/CQ-Roll Call, Inc./Getty Images

Congress Poised To Pass Sweeping Law Covering FDA And NIH

  • Download
  • <iframe src="https://www.npr.org/player/embed/503759592/503766913" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Hanna Barczyk for NPR

Patients Increasingly Influence The Direction Of Medical Research

  • Download
  • <iframe src="https://www.npr.org/player/embed/502904826/503558418" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

After several prominent safety problems with medical devices in hospitals emerged, the Food and Drug Administration inspected 17 hospitals across the country in late 2015 to assess their compliance with reporting regulations. Congressional Quarterly/CQ-Roll Call, Inc./Getty Images hide caption

toggle caption
Congressional Quarterly/CQ-Roll Call, Inc./Getty Images

Sarepta Therapeutics was awarded a voucher for a fast-track drug review by the Food and Drug Administration when the company's medicine for Duchenne muscular dystropy was approved Sept. 19. Now Sarepta is looking to sell the voucher to the highest bidder. Mick Wiggins/Ikon Images/Getty Images hide caption

toggle caption
Mick Wiggins/Ikon Images/Getty Images

A job reviewing drug applications at the Food and Drug Administration can be the springboard for a career in industry. Andrew Harnik/AP hide caption

toggle caption
Andrew Harnik/AP

Duchenne muscular dystrophy patients Jack Willis (center), Nolan Willis (right) and Max LeClaire, attended the opening of Sarepta Therapeutics new headquarters in Cambridge, Mass., in 2014. Boston Globe via Getty Images hide caption

toggle caption
Boston Globe via Getty Images

Controversy Continues Over Muscular Dystrophy Drug, Despite FDA Approval

  • Download
  • <iframe src="https://www.npr.org/player/embed/495174472/495295191" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Maria Fabrizio for NPR

Researchers Question Safety, Value Of Untested Stem Cell Treatments

  • Download
  • <iframe src="https://www.npr.org/player/embed/491372940/492674855" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript